Zelira Therapeutics Limited ZLDAF
Set alert
At close · Oct 30
- YTD
- -96.32%
- 1 year
- -95.50%
- Open
- 0.01
- Prev close
- 0.205
- Mkt cap
- 131.47K
- Vol
- 200
- Avg vol
- 11
- EPS
- -0.20
- P/E
- 0.00
More statistics
- Low
- 0.01
- High
- 0.01
News
7 months ago defenseworld.net
Zelira Therapeutics (OTCMKTS:ZLDAF) and Hyperion DeFi (NASDAQ:HYPD) Critical Analysis
Hyperion DeFi (NASDAQ: HYPD - Get Free Report) and Zelira Therapeutics (OTCMKTS:ZLDAF - Get Free Report) are both medical companies, but which is the superior stock? We will contrast the two…
9 months ago proactiveinvestors.com
Zelira secures transformative US$33 million funding for HOPE® 1 autism program
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) has secured a major funding milestone after its HOPE® 1 special purpose vehicle (SPV) signed definitive...
10 months ago defenseworld.net
Zelira Therapeutics (OTCMKTS:ZLDAF) Trading Up 13.9% – Here’s Why
Shares of Zelira Therapeutics Limited (OTCMKTS:ZLDAF - Get Free Report) were up 13.9% during mid-day trading on Monday. The stock traded as high as $0.2660 and last traded at $0.2660. Approximately…
-
10 months ago benzinga.com
'Trump to sign executive order reclassifying marijuana: Officials' -ABC Report
https://abcnews.go.com/Politics/trump-sign-executive-order-reclassifying-marijuana-officials/story?id=128472615
11 months ago defenseworld.net
Zelira Therapeutics (OTCMKTS:ZLDAF) Trading Down 4.4% – Here’s What Happened
Zelira Therapeutics Limited (OTCMKTS:ZLDAF - Get Free Report)'s share price dropped 4.4% during mid-day trading on Wednesday. The stock traded as low as $0.2056 and last traded at $0.2056.…
-
1 year ago benzinga.com
Marijuana Stock Movers For July 8, 2025
Marijuana Stock Movers For July 8, 2025
-
1 year ago benzinga.com
'GOP-Led Congressional Panel Demands Investigation On Biden's Marijuana Rescheduling Process, Citing 'Deviations' And 'Mental Health Hazards'' -Marijuana Moment Report
https://www.marijuanamoment.net/gop-led-congressional-panel-demands-investigation-on-bidens-marijuana-rescheduling-process-citing-deviations-and-mental-health-hazards/
-
1 year ago benzinga.com
Marijuana Stock Movers For May 8, 2025
Marijuana Stock Movers For May 8, 2025
-
1 year ago benzinga.com
Watching Cannabis Stocks; Marijuana Moment Reports 'Trump White House Invites Proposal On Federal Marijuana Legalization, Activist Says'
https://www.marijuanamoment.net/trump-white-house-invites-proposal-on-federal-marijuana-legalization-activist-says/
-
2 years ago benzinga.com
Cannabis Stock Gainers And Losers From August 5, 2024
Cannabis Stock Gainers And Losers From August 5, 2024
-
2 years ago benzinga.com
Marijuana Stock Movers For August 2, 2024
Marijuana Stock Movers For August 2, 2024
-
3 years ago benzinga.com
Bearish Monday For Marijuana Stocks - EVIO, Item 9 Labs Among Top Gainers
GAINERS: Gaby (OTC:GABLF) shares closed up 29.41% at $0.00
4 years ago proactiveinvestors.com
Zelira Therapeutics well placed to generate further growth in cash flow as commercialisation accelerates
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) is well placed to generate further growth in cash flow and revenue via its diversified income streams, with a suite of new products launched in H1…
4 years ago proactiveinvestors.com
Zelira Therapeutics receives A$1.292 million cash R&D tax incentive
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) has received a cash refund of A$1.292 million under the Australian Federal Government's Research and Development Tax Incentive Scheme. The funds…
4 years ago proactiveinvestors.com
Zelira Therapeutics receives 25% of US$1 million licensing fee from DRCN Holdings for EDCDM technology
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) has received US$250,000 of its upfront non-refundable, non-contingent licensing fee of US$1 million from DRCN Holdings LLC, with the remaining…
4 years ago proactiveinvestors.com
Zelira Therapeutics' Phase 1 dose escalation study in chronic pain patients on long-term opioid treatment published in peer-reviewed journal
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF)'s open-label dose-escalation trial results in chronic non-cancer pain patients have been published in the peer-reviewed journal Pain And Therapy. The…
4 years ago proactiveinvestors.com
Zelira Therapeutics expands into growing New Zealand cannabinoid-based medicines market
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) is expanding into the growing New Zealand cannabinoid-based medicines market by way of a five-year exclusive distribution agreement with NUBU…
4 years ago proactiveinvestors.com
Zelira Therapeutics gets ethics green light for Phase 2a trial of sports injury cannabinoid
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF), which develops clinically validated cannabis medications, has secured ethics approval for a Phase 2a clinical trial to assess the effectiveness of its…
5 years ago proactiveinvestors.com
Zelira Therapeutics develops enhanced solid-form cannabinoid production method, signs foundational licensing deal
Zelira Therapeutics Ltd (ASX:ZLD, OTCQB:ZLDAF) has opened new pathways to develop pharmaceutical-grade cannabidiol capsules and tablets with its proprietary Enhanced Distillate Capture and…
5 years ago proactiveinvestors.com
Zelira Therapeutics research-backed products behind its impressive growth
Zelira Therapeutics Ltd quarterly reads as a long list of highlights, which is testament to the work it is doing in the development of clinically validated cannabinoid medicines. The company has not…
5 years ago proactiveinvestors.com
Zelira Therapeutics gains substantial new US-based shareholder following US$5 million cap raise
Zelira Therapeutics Ltd has raised a total of US$5 million from a US-based family office fund to accelerate its growth initiatives. Zelira is a global leader in the research and development of…
5 years ago proactiveinvestors.com
Zelira Therapeutics set to launch suite of new cannabinoid-based products over FY22 and grow sales of existing products
Zelira Therapeutics Ltd's research and development (R&D) and commercialisation programs are expected to lead to the launch of a suite of new cannabinoid-based products over FY22. In FY21, the global…
5 years ago prnewswire.com
Zelira™ Launches RAF FIVE™ Acne Treatment Products Through Its Dermatology Focused Subsidiary
PHILADELPHIA, Sept. 23, 2021 /PRNewswire/ -- Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF), a global leader in the research and development of clinically validated cannabinoid medicines, is…
5 years ago proactiveinvestors.com
Zelira Therapeutics launches RAF FIVE™ CBD acne treatment products
Zelira Therapeutics Ltd, a leading global medicinal cannabis company, has launched its new line of CBD-based acne and skin products, RAF FIVE™. Developed in partnership with Harvard-trained and US…
5 years ago proactiveinvestors.com
Zelira Therapeutics expands into large German market via exclusive cannabis distribution agreement
Zelira Therapeutics Ltd has expanded into Europe via the large and growing German cannabinoid-based medicines market through an exclusive distribution agreement with Adjupharm GmbH, a German…
5 years ago proactiveinvestors.com
Zelira Therapeutics' commercialisation program to see launch of suite of new cannabinoid-based products over FY22
Zelira Therapeutics Ltd continues to focus on the expansion of commercialisation activities and revenue generation from its new clinically tested products, with the strategy expected to lead to the…
5 years ago proactiveinvestors.com
Zelira Therapeutics closes out FY21 with record cash receipts ahead of product launches
Zelira Therapeutics Ltd has capped off the 2021 financial year with record cash receipts as it looks ahead to product launches later this year. The cannabinoid medicines developer finished the June…
5 years ago proactiveinvestors.com
Zelira Therapeutics to go head-to-head with big pharma in US clinical pain trial
Zelira Therapeutics (ASX:ZLD) (OTCMKTS:ZALDF) has secured Institutional Review Board (IRB) approval for a pain observational trial to take place in the US. The cannabinoid medicines developer is set…